NGM Biopharmaceuticals, Inc.
Anti-C3 antibodies
Last updated:
Abstract:
The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.
Status:
Grant
Type:
Utility
Filling date:
1 Apr 2019
Issue date:
5 Oct 2021